Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Addition Of Lunesta To Lexapro Provides Benefits, Study Finds

This article was originally published in The Pink Sheet Daily

Executive Summary

The sleep aid combined with Lexapro shows a significant improvement in sleep measures compared to Lexapro and placebo.

You may also be interested in...



Sepracor Sees Sweet Dreams For Lunesta Despite Generic Ambien Next Year

Firm says formulary placement of the sleep aid will help mitigate Rx erosion following the launch of generic Ambien.

Lunesta’s Expanded Sales Force Will Focus On Maintenance Use

Sepracor said it does not plan to use negative publicity about side effects with Sanofi-Aventis’ Ambien to gain a competitive edge.

Sandoz Optimistic On Biosimilars As It Reprioritizes US Portfolio

Sandoz US president Carol Lynch talked to Scrip about its changing US portfolio, which will emphasize biosimilars, as the Novartis unit is poised to divest most of its US generics portfolio to Aurobindo.

Topics

UsernamePublicRestriction

Register

PS063628

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel